Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Grupo Español de Investigación en Cáncer de Ovario
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04539327CT.gov Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study | — | Completed | — | — | — |
NCT04227522CT.gov Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients | — | Completed | — | — | — |
NCT03824704CT.gov A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | — | Terminated | — | — | — |
NCT03552471CT.gov Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | — | Completed | — | — | — |
NCT03522246CT.gov A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Peritoneal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rucaparib (this asset) | Grupo Español de Investigación en Cáncer de Ovario | P3 | B · 59 |
| Cis-Diamminedichloroplatinum Ii | GOG Foundation | P3 | BBB |
| Carboplatin | University of Washington | P3 | BBB |
| Nogitecan | Sichuan Baili Pharmaceutical Co., Ltd. | P3 | BBB |
| Adriamycin | Sichuan Baili Pharmaceutical Co., Ltd. | P3 | BBB |
| Pegfilgrastim | TORL Biotherapeutics, LLC | P2/3 | BBB |
| Nivestim | Roswell Park Cancer Institute | P2 | BBB |
| Durvalumab | National Cancer Institute (NCI) | P2 | BB |
| Mirvetuximab Soravtansine | AbbVie | P3 | BB |
+42 more in the Primary Peritoneal Carcinoma cohort
Other indications for Rucaparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Peritoneum Cancer | — | P3 | BB · 66 |
| Ovarian Cancer | — | P3 | B · 61 |
| Ovarian Carcinoma | — | P3 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rucaparib in Primary Peritoneal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rucaparib-primary-peritoneal-carcinoma-104752
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →